ProThera Biologics and Takeda Enter Global Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)

ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited [TSE:4502/NYSE:TAK] (“Takeda”) today announced that they have entered into a global licensing agreement to develop a novel plasma-der …
( read original story …)

---